M&A / Deals Cancer biotech Parabilis books record IPO, raising $670m PharmaphorumParabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide.OncologyRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) Pharmaphorum Parabilis has broken the IPO record set by Kailera in April, packing its coffers as it starts an ambitious trial programme for lead drug zolucatetide. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Alzecure enters collaboration and with Lilly for Alzheimer’s projectNext: Aditxt and Ignite announce merger plans with strategic partner Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
